H1 2020 Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Pipeline Review - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report provides an overview of the Multiple System Atrophy (Central Nervous System) pipeline landscape.

Multiple system atrophy (MSA) or Shy-Drager syndrome is a neurological disorder that impairs body's involuntary functions (blood pressure, heart rate, bladder function and digestion). Symptoms include rigid muscles, bradykinesia, Tremors, dysarthria, dysphagia, constipation, incontinence and irregular heartbeat. Treatment is aimed at relieving symptoms with anti-Parkinson's medications.

It provides comprehensive information on the therapeutics under development for Multiple System Atrophy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Multiple System Atrophy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 5, 8 and 3 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Multiple System Atrophy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Companies Mentioned

• 1st Bio Therapeutics Inc
• Alterity Therapeutics Ltd
• Arvinas Inc
• Biogen Inc
• Biohaven Pharmaceutical Holding Company Ltd
• Corestem Inc
• Denali Therapeutics Inc
• EmeraMed Ltd
• ICB International Inc
• Inhibikase Therapeutics Inc
• Ionis Pharmaceuticals Inc
• MitoDys Therapeutics Ltd
• Modag GmbH
• Neuropore Therapies Inc
• Newron Pharmaceuticals SpA
• ProMIS Neurosciences Inc
• Stealth BioTherapeutics Corp
• United Neuroscience Ltd
• Voyager Therapeutics Inc

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Multiple System Atrophy (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Multiple System Atrophy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

• Introduction
• Report Coverage
• Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Overview
• Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Therapeutics Development
• Pipeline Overview
• Pipeline by Companies
• Pipeline by Universities/Institutes
• Products under Development by Companies
• Products under Development by Universities/Institutes
• Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Therapeutics Assessment
• Assessment by Target
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type
• Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Companies Involved in Therapeutics Development
• Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Drug Profiles
• R&D Progress
• Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Dormant Projects
• Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Product Development Milestones
• Featured News & Press Releases
• Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/wxdwj1